GRO Biosciences has developed a platform to produce high-value protein therapeutics that address both problems of cost and half-life. Therapeutic proteins are often made in expensive systems because they have chemical bonds that do not form in microbes. These bonds can also break in blood plasma, causing poor serum half-life. By using microbes with an expanded genetic code, GRO Biosciences is developing therapeutic proteins with new stabilizing bonds to enable inexpensive microbial fermentation, fast production times, and long serum half-life. Its technologies can produce a broad set of high value biobetters which can be implemented in various biologics including insulin, interferon, Erythropoietin, and human growth hormone, each potentially a billion-dollar market.